Candriam S.C.A. Apellis Pharmaceuticals, Inc. Put Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
309Shares Held
115MCall Options Held
3.37MPut Options Held
816K-
Wellington Management Group LLP Boston, MA15.6MShares$437 Million0.08% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$334 Million14.88% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.1MShares$312 Million4.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.82MShares$275 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.8MShares$163 Million0.01% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $3.08B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...